来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置首页>技术资料首页>行业动态>公司动态>Thermo Fisher完成收购Life Technologies

Thermo Fisher完成收购Life Technologies

Thermo Fisher2014年2月24日 12:03 点击:6054

 赛默飞世尔科技,Thermo Fisher Scientific,  美国Life Technologies

2014年2月3日 Thermo Fisher完成收购Life Technologies收购价格为136亿美元并承担其15亿美元债务。

此前,美国联邦贸易委员会有条件地批准了此项交易,即赛默飞世尔需要将细胞培养、基因调节、磁珠业务相关资产出售给GE医疗集团。

赛默飞世尔还表示,该公司的财报将新增一项业务即生命科学解决方案,从2014年1月1日起,赛默飞世尔财报由生命科学解决方案、实验室产品和服务、分析仪器以及专业诊断四部分组成。

原Life Technologies的首席运营官Mark Stevenson被任命为赛默飞世尔执行副总裁,生命科学解决方案业务部门总裁。前Life Technologies董事长兼首席执行官Greg Lucier没有加入合并后的公司。去年秋天,他被任命为桑福德-伯纳姆医学研究所主席。

赛默飞完成对Life Technologies公司的收购 增加第四个财务报告部分


 

2014210日,上海 —— 科学服务领域的世界领导者赛默飞世尔科技(以下简称:赛默飞)24日宣布已完成对Life Technologies(纳斯达克代码:LIFE)的全面收购,收购总价约合136亿美元(以每股76.13美元的现金价格),并承担其15亿美元债务。该收购在收到所有监管部门批准文件后全部完成。

“我们很高兴宣布这项收购现在已全部完成,并对随之而来的机会感到兴奋不已,它将在服务研究、生命科学、专业诊断和相关应用市场为我们创造无与伦比的领导地位,”赛默飞总裁及首席执行官葛士柏表示:“我们联合后能够提供的尖端技术,诸如基因组学和蛋白质组学,将能加快生命科学研究的进展,提高人类健康发展水平。同时我们在生物科学和生物工艺方面优势互补,将加速新药发现、研发和生产的过程。随着Life Technologies的加入,我们在帮助我们的客户实现目标、提高创新能力和生产力方面将变得更加强大。”
 
业务集团

在收购了Life Technologies后,赛默飞建立了一个新的业务集团——生命科学产品和服务集团。原Life Technologies首席运营官Mark Stevenson被任命为执行副总裁兼生命科学产品和服务总裁,直接向葛士柏汇报。
 

自2014年1月1日起,公司财务报告将以下列四个业务部分呈现,其变化如下:

  • 新的生命科学产品和服务业务由原Life Technologies的大部分业务和赛默飞生物科学业务组成。
  •  赛默飞全球化学业务将从生物科学业务中移出,并入实验室产品与服务业务。
  • 生物科学业务转移后,赛默飞分析技术业务将改名为分析仪器业务。
  • Life Technologies的两个较小的专业诊断业务将成为专业诊断业务的一部分。
  • 如先前已宣布,赛默飞同意以10.6亿美元向GE出售细胞培养(血清和培养基)、基因调节和磁珠业务 

由于交易完成,Life Technologies的股票在收购完成当天收盘后在纳斯达克股票市场停止交易。

 


关于赛默飞世尔科技
赛默飞世尔科技(纽约证交所代码:TMO)是科学服务领域的世界领导者。公司年销售额170亿美元,在50个国家拥有员工约50,000人。我们的使命是帮助客户使世界更健康、更清洁、更安全。我们的产品和服务帮助客户加速生命科学领域的研究、解决在分析领域所遇到的复杂问题与挑战,促进医疗诊断发展、提高实验室生产力。借助于Thermo Scientific、Life Technologies、Fisher Scientific和Unity™ Lab Services四个首要品牌,我们将创新技术、便捷采购方案和实验室运营管理的整体解决方案相结合,为客户、股东和员工创造价值。欲了解更多信息,请浏览公司网站:www.thermofisher.com
 
关于赛默飞世尔科技中国
赛默飞世尔科技进入中国发展已有30多年,在中国的总部设于上海,并在北京、广州、香港、台湾、成都、沈阳、西安、南京、武汉等地设立了分公司,员工人数超过2400名。我们的产品主要包括分析仪器、实验室设备、试剂、耗材和软件等,提供实验室综合解决方案,为各行各业的客户服务。为了满足中国市场的需求,现有5家工厂分别在上海、北京和苏州运营。我们在北京和上海共设立了5个应用开发中心,将世界级的前沿技术和产品带给国内客户,并提供应用开发与培训等多项服务;位于上海的中国创新中心结合国内市场的需求和国外先进技术,研发适合中国的技术和产品;我们拥有遍布全国的维修服务网点和特别成立的中国技术培训团队,在全国有超过400 名经过培训认证的、具有专业资格的工程师提供售后服务。我们致力于帮助客户使世界更健康、更清洁、更安全。欲了解更多信息,请登录网站 www.thermofisher.cn

 

Thermo Fisher Scientific Completes Acquisition of Life Technologies Corporation

NYSE:
TMO
 
"We are pleased to announce that this transaction is now complete, and excited about our opportunity to create unrivaled leadership in serving research, life sciences, specialty diagnostics and applied markets"
 

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of Life Technologies Corporation (NASDAQ: LIFE) for $76.13 ($76.1311786) in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of $1.5 billion in net debt. The completion of the transaction follows the receipt of all required regulatory approvals.

“We are pleased to announce that this transaction is now complete, and excited about our opportunity to create unrivaled leadership in serving research, life sciences, specialty diagnostics and applied markets,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Our combined offering provides cutting-edge technologies, such as genomics and proteomics, to accelerate life sciences research and improve human health. And our complementary strengths in biosciences and bioprocessing will accelerate drug discovery, development and production. With the addition of Life Technologies, we are in an even stronger position to help our customers achieve their goals for innovation and productivity.”

Business Segments

With the acquisition of Life Technologies, Thermo Fisher has established a new reporting segment, called Life Sciences Solutions. Mark Stevenson, who served as chief operating officer of Life Technologies, has been named an executive vice president and president of Life Sciences Solutions, reporting directly to Casper.

Effective January 1, 2014, the company’s financial performance will be reported in four segments reflecting the following changes:

  • The new Life Sciences Solutions Segment will consist of the majority of the former Life Technologies and Thermo Fisher Biosciences businesses.
  • Thermo Fisher’s Global Chemicals business will move from the Biosciences business to the Laboratory Products and Services Segment.
  • Thermo Fisher’s Analytical Technologies Segment will be renamed Analytical Instruments to reflect the transfer of the Biosciences businesses to other segments, as mentioned above.
  • Two small specialty diagnostics businesses within Life Technologies will become part of the Specialty Diagnostics Segment.
  • As previously announced, Thermo Fisher has agreed to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for $1.06 billion.

In connection with the completion of the transaction, Life Technologies stock ceased trading on The NASDAQ Stock Market following market close today.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visitwww.thermofisher.com.

 

(来源: Thermo Fisher )


全年征稿 / 资讯合作

联系邮箱:kefu@labbase.net

版权与免责声明

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, //www.next-search.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。